Liver Regeneration Clinical Trial
Official title:
Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor Hepatectomy: An Open Label Randomised Trial
The goal of this open label randomized trial is to understand the role of oral ursodeoxycholic acid(UDCA) supplementation in the liver regeneration (in terms of liver function and anatomical growth) following right lobe donor hepatectomy. The main question it aims to answer are: - Does Ursodeoxycholic acid supplementation on patients undergoing donor hepatectomy improve anatomical liver regeneration after partial hepatectomy as compared to control group. - Does ursodeoxycholic acid improve liver regeneration in terms of liver function tests and biomarkers of liver regeneration(HGF, IL6, TNF Alpha, AFP, TGF Beta) as compared to control group.
This open label randomized control study aims to analyze the effect of ursodeoxycholic acid supplementation on liver regeneration following a right donor hepatectomy. All eligible live donors who undergo right donor hepatectomy during the study period will be included in the study and randomized into two groups. One group will receive Tab. UDCA 450mg twice daily for 10 days and the other group will not receive Tab UDCA. Live donors who are not willing to participate in the study, have hypersensitivity to UDCA or have used Tab UDCA in the past 2 weeks, will be excluded from the study. All live donors will be screened in the pre-operative period in the outpatient department. Pre- operative, intra-operative and post-operative data will be collected from medical records, electronic hospital information system (HIS) and radiological images collected from the hospital Picture archiving and communication system(PACS). The enrolled subjects will be followed up till for a period of 14 days after the donor hepatectomy till Non contrast CT Abdomen is done and regenerated liver volumes are analyzed. The anatomic(volumetric), functional(liver function tests) and regenerative biomarkers( HGF, TNF-Alpha, IL6, AFP, TGF-Beta) will be compared between the two groups. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Recruiting |
NCT04178759 -
Impact of Chemotherapy and Regenerative Markers of Liver Regeneration After Liver Resection for Liver Metastases
|
N/A | |
Completed |
NCT04565535 -
Effect of Novel Donor Lifestyle Optimisation Protocol on Liver Regeneration in Live Liver Donors
|
N/A | |
Recruiting |
NCT06126419 -
Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration
|
N/A | |
Recruiting |
NCT02113059 -
Platelets in Liver Regeneration
|
N/A | |
Completed |
NCT00957619 -
Study of the Protective Effect of Mechanism of Pentoxyfilline After Major Liver Resection Under Inflow Occlusion (Pringle Manoeuvre)
|
Phase 4 | |
Completed |
NCT02945059 -
Reversible Portal Vein Embolization Before Major Hepatectomy
|
N/A | |
Recruiting |
NCT04107324 -
ARAPS Study on Accelerated Liver Regeneration
|
N/A | |
Completed |
NCT05459883 -
Splenic Artery Ligation and Portocaval Shunt in Small-for-size Syndrome
|
||
Recruiting |
NCT02327832 -
Safety Study of Liver Regeneration Therapy Using Cultured Autologous BMSCs
|
Phase 1 | |
Enrolling by invitation |
NCT01924741 -
Registry of Major Liver Resections Including ALPPS and Other Liver Resections in Two Stages
|
N/A |